David Meek, departing Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)
August 8, 2023 05:20 PM EDTUpdated August 9, 07:31 AM
People
Financing

Mi­rati an­nounces CEO res­ig­na­tion, then a $300M pub­lic of­fer­ing af­ter dis­clos­ing clin­i­cal plans

Kyle LaHucik

Senior Reporter

David Meek, the CEO of Mi­rati Ther­a­peu­tics, has re­signed from the biotech and its board, the San Diego drug de­vel­op­er said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times